Meeting
2013 ASCO Annual Meeting
A phase ll study of new combination regimen with trastuzumab, S-1, and CDDP in HER2-positive advanced gastric cancer (HERBIS-1).
Authors
Keisuke Koeda
Department of Surgery, Iwate Medical University School of Medicine, Morioka, Japan
Keisuke Koeda , Naotoshi Sugimoto , Junji Tanaka , Masahiro Tsuda , Wataru Okamoto , Hiroyuki Okuda , Hiroshi Imamura , Jin Matsuyama , Toshio Shimokawa , Daisuke Sakai , Norimasa Fukushima , Yukinori Kurokawa , Yoshito Komatsu , Toshimasa Tsujinaka , Hiroshi Furukawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
UMIN000005739
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4072)
DOI
10.1200/jco.2013.31.15_suppl.4072
Abstract #
4072
Poster Bd #
20B
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase II study (KSCC/HGCSG/CCOG/PerSeUS1501B) of trastuzumab plus S-1 and oxaliplatin for HER2-positive advanced gastric cancer.
First Author: Katsunori Shinozaki
Poster
2013 Gastrointestinal Cancers Symposium
A phase ll study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer (HERBIS-1).
First Author: Naotoshi Sugimoto
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.
First Author: Ali Fawaz
Poster
2018 ASCO Annual Meeting
Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study.
First Author: Feng Wang